International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationRTOG 0417: Efficacy of Bevacizumab in Combination With Definitive Radiation Therapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma
Introduction
In the management of locally advanced cervical carcinoma, concurrent chemoradiation has led to significant improvements over radiation therapy alone 1, 2, 3, 4, 5, 6. However, patients still experience unacceptably high rates of local and distant failure. Overexpression of vascular endothelial growth factor (VEGF) is common in both cervical squamous cell carcinoma and adenocarcinoma, and this overexpression is correlated with compromised outcome 7, 8, 9, 10, 11, 12. For this reason, VEGF inhibitors such as bevacizumab are increasingly being incorporated into standard therapeutic regimens in an effort to improve outcomes. The Gynecology Oncology Group (GOG) evaluated single-agent bevacizumab, at a dosage of 15 mg/kg every 21 days, in a phase II trial for patients with recurrent or metastatic cervical squamous or adenosquamous carcinoma who had experienced progression after 1 or 2 cytotoxic chemotherapy regimens (13). The majority of patients had undergone radiation therapy and at least 1 regimen of chemotherapy. The results were favorable in comparison with historical control individuals, with 24% of patients being without progression after 6 months. The authors recommended further evaluation in a phase III trial, the basis for GOG 240 14, 15, which evaluated the addition of bevacizumab to cisplatin and paclitaxel or cisplatin and topotecan as first-line therapy for chemotherapy-naive patients with Stage IVB or recurrent squamous or adenocarcinoma not amenable to surgery or radiation therapy. Cycles were repeated every 21 days until disease progression, unacceptable toxicity, or complete response occurred. Importantly, patients were eligible if they had just received sensitizing chemotherapy concurrent with radiation treatment but were otherwise chemotherapy naive. This trial was a 2 × 2 factorial randomization to 2 different chemotherapy doublets. The cisplatin and topetecan doublet was not found to be better than cisplatin and paclitaxel at the first interim analysis. The second interim analysis lumped all cytotoxic chemotherapy together and compared the group given chemotherapy alone with the group who received chemotherapy plus bevacizumab. The results showed a striking improvement in overall survival (OS) with the addition of bevacizumab compared with either chemotherapy doublet alone, and there was no decline in health-related quality of life with the addition of bevacizumab. The median OS for the 225 patients who received bevacizumab in addition to chemotherapy was 17 months, versus 14 months for the 227 patients who received the chemotherapy doublet alone. The results were published in abstract form after the second planned interim analysis crossed the threshold for efficacy that was predefined in the trial.
For this study, the selection of 10 mg/kg of bevacizumab every 2 weeks was based on the compilation of trials of bevacizumab with chemotherapy and chemoradiation therapy at the time. The dosage of 10 mg/kg was known to be safe when combined with both abdominal and pelvic radiation therapy 16, 17.
Radiation Therapy Oncology Group (RTOG) 0417 was a phase II trial evaluating the addition of bevacizumab to weekly cisplatin concurrent with radiation treatment for patients with locally advanced cervical carcinoma. The study was powered for the primary endpoint of acute toxicity defined as treatment-related adverse events (AEs) and serious adverse events (SAEs). We previously reported that bevacizumab in addition to standard pelvic chemoradiation therapy for locally advanced cervical cancer was feasible and safe with respect to the protocol-specified treatment-related SAEs and AEs (18). This report focuses on the secondary efficacy endpoint results.
Section snippets
Patient eligibility
Patients were eligible if they had histologic proof of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix, including International Federation of Gynecologists and Obstetricians (FIGO) Stage IIB to IIIB disease, or patients with FIGO Stage IB to IIA disease who had biopsy-proven pelvic node metastases, tumor size exceeding 5 cm, or both. The previous report contains a detailed account of other eligibility criteria (18).
Radiation, cisplatin chemotherapy, and bevacizumab treatment
The details of treatment have been
Patients
RTOG 0417 opened to accrual in August 2006 and completed accrual in August 2009. Sixty patients from 28 institutions were enrolled. Forty-nine patients were evaluable. Of the 11 patients excluded from analysis, 1 patient did not receive protocol treatment; 4 patients did not have blood work done, or it was done outside the allowable window; 1 patient had a biopsy performed <7 days before registration; 1 patient had FIGO Stage IVA disease; 1 patient had a hemoglobin level of 9.0 g/dL; 1 patient
Discussion
The addition of bevacizumab to weekly concurrent cisplatin and radiation treatment was well tolerated and was associated with encouraging OS and locoregional control in this phase II study. GOG 240 showed an OS improvement with the addition of maintenance bevacizumab to chemotherapy for chemotherapy-naive patients (those who had undergone sensitizing chemotherapy with radiation therapy but who were otherwise chemotherapy naive were eligible) with persistent, recurrent, or metastatic cervical
Conclusion
In this study, bevacizumab in combination with standard pelvic chemoradiation for locally advanced cervical cancer showed efficacy results that are promising and warrant further investigation.
References (19)
Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care
Semin Radiat Oncol
(2000)- et al.
Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: Impact on progression-free survival
Cancer Lett
(2002) - et al.
Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix
Int J Radiat Oncol Biol Phys
(2002) - et al.
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy
Int J Radiat Oncol Biol Phys
(2003) - et al.
Combining radiotherapy and angiogenesis inhibitors: Clinical trial design
Int J Radiat Oncol Biol Phys
(2006) - et al.
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: Preliminary results of RTOG 0417
Int J Radiat Oncol Biol Phys
(2012) - et al.
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
N Engl J Med
(1999) - et al.
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
N Engl J Med
(1999) - et al.
Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
N Engl J Med
(1999)
Cited by (101)
Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care
2024, International Journal of Radiation Oncology Biology PhysicsLong-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage “bulky” cervical cancer and survival impact of histological subtype
2023, Journal of the Formosan Medical AssociationCitation Excerpt :Although the meeting abstract of OUTBACK trial displayed no survival benefit with adjuvant chemotherapy (Carboplatin + Paclitaxel) following chemoradiation compared with definite chemoradiation for locally advanced cervical cancer, the formal published data is still warranted for more detailed interpretation of subgroup analysis.46 Moreover, adding a target agent, such as bevacizumab, into CCRT might be another treatment option for bulky stage IB-IIIB cervical cancer based on the RTOG 0417 trial, which showed 3-year OS, disease-free survival, and locoregional failure rates of 81.3%, 68.7%, and 23.2%, respectively.47 Nevertheless, it remains unknown which treatment strategy or novel agents could attain the best therapeutic efficacy for AC/ASC histology.
Invasive cervical cancer
2023, DiSaia and Creasman Clinical Gynecologic OncologyA systematic review and meta-analysis of adjuvant chemotherapy after chemoradiation for locally advanced cervical cancer
2022, Critical Reviews in Oncology/HematologyCitation Excerpt :Considering this and our previous meta-analysis (Horeweg et al., 2021), we can only conclude that there is no benefit of adjuvant chemotherapy to chemoradiation and brachytherapy in unselected locally advanced cervical cancer patients. Now, the focus of research locally advanced cervical cancer has moved to targeted therapies such as anti-PD(L)1 (Mayadev et al., 2020; Merck Sharp & Dohme Corp. et al., 2020; Duska et al., 2020; Institute Curie and Bristol-Myers Squibb, 2017; Gustave Roussy, 2018; Grupo Español de Investigación en Cáncer de Ovario et al., 2019), anti-CTLA-4 (Mayadev et al., 2019; NCT, 2021), anti-VEGF (National Cancer Institute and Radiation Therapy Oncology Group, 2006; Air Force Military Medical University, China, 2019; Schefter et al., 2014; Lu et al., 2021) and anti-EGFR agents (Zhujiang Hospital, 2018; Chen et al., 2017; Qu et al., 2019; Rawat et al., 2020). Nonetheless, the cervical cancer research community should learn from the message hidden in the outcomes of all trials on adjuvant chemotherapy: non-selective allocation of adjuvant systemic treatment was not successful.
Pre-treatment hematological parameters as a cost effective predictive marker for response to concurrent chemo radiation in locally advanced cervical cancer
2022, Cancer Treatment and Research Communications
Supported by RTOG grant U10 CA21661, CCOP grant U10 CA37422, and ATC grant U24 CA81647 from the National Cancer Institute (NCI).
This article's contents are the sole responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Conflict of interest: none.